AU4485689A - Oral dosage forms of omega-3 polyunsaturated acids - Google Patents

Oral dosage forms of omega-3 polyunsaturated acids

Info

Publication number
AU4485689A
AU4485689A AU44856/89A AU4485689A AU4485689A AU 4485689 A AU4485689 A AU 4485689A AU 44856/89 A AU44856/89 A AU 44856/89A AU 4485689 A AU4485689 A AU 4485689A AU 4485689 A AU4485689 A AU 4485689A
Authority
AU
Australia
Prior art keywords
omega
dosage forms
oral dosage
polyunsaturated acids
polyunsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44856/89A
Inventor
Roger Andre Pluss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
JB Tillott Ltd
Original Assignee
JB Tillott Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JB Tillott Ltd filed Critical JB Tillott Ltd
Publication of AU4485689A publication Critical patent/AU4485689A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
AU44856/89A 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids Abandoned AU4485689A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids
GB8824709 1988-10-21

Publications (1)

Publication Number Publication Date
AU4485689A true AU4485689A (en) 1990-05-14

Family

ID=10645593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44856/89A Abandoned AU4485689A (en) 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids

Country Status (4)

Country Link
AU (1) AU4485689A (en)
CA (1) CA2000881A1 (en)
GB (1) GB2223943A (en)
WO (1) WO1990004391A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661297B2 (en) * 1991-01-24 1995-07-20 Martek Corporation Microbial oil mixtures and uses thereof

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
FR2663222A1 (en) * 1990-06-13 1991-12-20 Medgenix Group Sa OILY LIQUID MICROCAPSULE.
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
EP0855908B1 (en) * 1995-12-11 2002-02-06 Omni Nutraceuticals, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (en) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh Oral dosage form containing CO-3-unsaturated fatty acids
US20040176451A1 (en) * 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
CA2499501A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
CA2515328A1 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
NZ569676A (en) 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CN104288138A (en) * 2008-12-31 2015-01-21 尼特罗米加公司 Nutraceuticals containing nitro fatty acids
PT3037089T (en) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
EP2424356B1 (en) 2009-04-29 2017-08-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
RU2624506C2 (en) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Pharmaceutical compositions containing epa and cardiovascular agents and their application methods
EP3698781A1 (en) 2009-06-15 2020-08-26 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
RU2012116079A (en) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи PHARMACEUTICAL COMPOSITION, INCLUDING OMEGA-3 FATTY ACID AND HYDROXY DERIVATED STATIN AND WAYS OF ITS APPLICATION
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
CA2860512C (en) 2012-01-06 2019-02-05 Omthera Pharmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP6173437B2 (en) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド Statins and omega-3 fatty acid compositions
PT3363433T (en) 2012-06-29 2021-02-15 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6018712B2 (en) * 2014-04-25 2016-11-02 株式会社山田養蜂場本社 Absorption accelerator for unsaturated fatty acids
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
SE8604117D0 (en) * 1986-09-29 1986-09-29 Kabivitrum Ab COMPOSITION

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661297B2 (en) * 1991-01-24 1995-07-20 Martek Corporation Microbial oil mixtures and uses thereof

Also Published As

Publication number Publication date
GB2223943A (en) 1990-04-25
CA2000881A1 (en) 1990-04-21
WO1990004391A1 (en) 1990-05-03
GB8824709D0 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
AU4485689A (en) Oral dosage forms of omega-3 polyunsaturated acids
AU4081489A (en) Fatty acid therapy and compositions
AU3896789A (en) Fatty acid composition
AU1241295A (en) Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
AU3065895A (en) Sunflower products having lower levels of saturated fatty acids
AU3558989A (en) Threaded dental anchor
AU2122688A (en) Microorganism production of omega-3 (n-3) lipids
IL92545A0 (en) Preparation of 2-chloropyridine-3-carboxylic acid esters
IL78528A (en) Difluoro-naphthyridine-and trifluoro-quinoline-carboxylic acids and esters and salts thereof and pharmaceutical compositions containing them
AU1060488A (en) Licidal compositions containing carboxylic acids
NZ216971A (en) Phosphonate esters and pharmaceutical compositions
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
GB8812653D0 (en) Pharmaceutical composition based on high concentration esters of docosahexaenoic acid
GB2172597B (en) Polymerisation of fatty acids
AU6201386A (en) Preparation of esters
AU5076390A (en) Oral preparation
EP0227301A3 (en) Process for the preparation of n-formyl-alpha-l-aspartyl-l-phenylalanine methyl ester
AU1258988A (en) Esters of oxalofluoride
AU5882186A (en) 3-(substituted)propenylaminothiazol-ylcephalosporanic acids and esters thereof
ZA936233B (en) Method for the safe administration of fatty acids
IL85776A0 (en) Pharmaceutical compositions comprising certain algae and polyunsaturated fatty acids and their preparation
ZA895758B (en) Polyunsaturated fatty acids
AU582678B2 (en) Heterocyclylalkyl esters of 2-imidazolinonenicotinic acids
AU552612B2 (en) Preparation of acids and esters
AU586257B2 (en) Preparation of 3-amino-4-hydroxybenzoic acids